Mood Emot.  2018 Nov;16(3):140-151. 10.0000/me.2018.16.3.140.

Comparison of the Bupropion versus Aripiprazole Adjunctive Therapy for the Treatment of Female Depression : Post-Hoc Analyses from a Randomized Prospective Open-Label Multi-Center Study

Affiliations
  • 1Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center, Daegu, Korea. annemyanne@hanmail.net
  • 2Department of Neuropsychiatry, Dongguk University Kyungju Hospital, Kyungju, Korea.
  • 3Department of Neuropsychiatry, Daegu Fatima Hospital, Daegu, Korea.
  • 4Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, Korea.
  • 5Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Korea.
  • 6Department of Neuropsychiatry, College of Medicine, Pochon Cha University, Cha Hospital, Gumi, Korea.

Abstract


OBJECTIVES
The purpose of this study was to examine effects of adjunctive aripiprazole versus bupropion, on depressive symptoms of female depression.
METHODS
Sixty six female patients with major depressive disorders were enrolled from a six-week, randomized prospective open-label multi-center study. Participants were randomized to receive aripiprazole (2.5-10 mg/day) or bupropion (150-300 mg/day). Montgomery Asberg Depression Rating Scale, 17-item Hamilton Depression Rating scale (HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales (anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms.
RESULTS
Overall, both treatments improved depressive symptoms, without causing serious adverse events. There were significant differences in the HAM-D17 total score (p=0.046) and CGI-S (p=0.004), between aripiprazole and bupropion augmentation, favoring aripiprazole over bupropion. Aripiprazole revealed significantly greater effect size in depressed mood (p=0.006), retardation (p=0.005), anxiety psychic (p=0.032), and general somatic symptom (p=0.01).
CONCLUSION
While both treatments were effective, results of this study suggested that aripiprazole may be preferable, in treating general and core symptoms of female depression.

Keyword

Aripiprazole; Bupropion; Treatment resistant depression; Female depression; Anxiety; Somatic symptom

MeSH Terms

Anxiety
Aripiprazole*
Bupropion*
Depression*
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Fatigue
Female*
Humans
Iowa
Prospective Studies*
Sleep Initiation and Maintenance Disorders
Weights and Measures
Aripiprazole
Bupropion
Full Text Links
  • ME
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr